Teratogenic activity of lithium carbonate: an experimental update.
The teratogenic potential of lithium carbonate was re-examined using mouse embryos as an experimental model. Externally it was found that, like many other psychoactive drugs, it exhibits a teratogenic activity that is confined to the development of the central nervous system. When administered intraperitoneally to pregnant females in doses ranging from 330 to 340 mg/kg at the very beginning of the ninth gestation day, i.e., during the critical period of the neural tube closure, it is embryotoxic, causes retardation of development, and induces the "neurotropic syndrome of malformations" comprising exencephaly, craniorachischisis, rachischisis, kinking of the spinal cord, and dilation of the fourth brain ventricle. Depending on the exact time of gestation when lithium carbonate is administered, the frequencies of exencephaly and spinal kinking after treatment 1 hour into the ninth day are compared with those after treatment 2 or 3 hours into the ninth day, incidence of exencephaly is increased at the later time and the incidence of spinal kinking is decreased.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D001921:Brain / Q000002:abnormalities; D005260:Female; D007928:Lethal Dose 50; D008094:Lithium / Q000633:toxicity*; D016651:Lithium Carbonate; D051379:Mice; D008815:Mice, Inbred Strains; D011247:Pregnancy; D013116:Spinal Cord / Q000002:abnormalities; D013723:Teratogens
D013723:Teratogens; D016651:Lithium Carbonate; D008094:Lithium